100% of primary human hepatocytes infected with an adenoviral vector carrying,8-galactosidase expressed the exogenous gene. Expression was also achieved in > 40% of adult mouse hepatocytes in vivo.
Introduction
Despite tremendous progress in medicine today, many genetic disorders remain without adequate treatment. A gene augmentation or replacement regimen is therefore an innovative and potentially new solution to this inadequacy.
We have previously proposed that the urea cycle defect ornithine transcarbamylase (OTC)' deficiency is an excellent choice for gene therapy research, since it occurs frequently by new mutation, is cured by hepatic transplantation in some patients, has two mouse models available for experimentation, and the gene is well characterized ( 1, 2). Furthermore, drug therapy for the acute hyperammonemia that occurs during catabolic episodes has shown some benefit, suggesting that longor short-term or partial OTC gene expression may have clinical utility if in vivo delivery and expression could be achieved.
In recent years, several reports have indicated the utility of defective adenoviral vectors for gene therapy (3) (4) (5) (6) (7) . Adenoviruses have several features that make them attractive as potential gene therapy agents. They do not require cell proliferation to transfer gene expression (8) , can presently accommodate . 8 kb of foreign DNA, and can easily be produced and purified at titers > 109 ml (9) . In addition, although adenovirus serotype 5 in subgenus C is a common cause of upper respiratory tract infection in children < 5 yr of age (10) , this virus is not associated with serious illness in immunologically competent individuals or malignancies (8, (11) (12) (13) . Furthermore, for more than two decades, unattenuated adenoviruses have been successfully used as oral vaccines ( 14) . This evidence of the safety ofadenovirus reinforces the potential significance ofthis system as a gene therapy tool. For human gene therapy purposes, evaluation ofthe vector ofchoice in human target tissue is essential. Until now, there have been no studies on the use of recombinant adenovirus in primary human hepatocytes despite several successful studies in rodents (3-7).
Methods
Construction ofAdHCMVspJLacZ and AdSRahOTC. The LacZ and the hOTC genes were inserted in the El region into different compensatory deletions. The deletions into which the genes were inserted were generated using the same initial plasmid, pXC I ( 15) , which contains the first 5,788 bp ofthe adenovirus type 5 (Ad5) genome inserted into the BamHI and SalI sites ofpBR322. pXCX2, the plasmid into which the hOTC gene was inserted, was generated from pXCl by deleting Ad5 sequences from the PvuI site at 452 bp to the BglII site at 3328 bp, and inserting an XbaI cloning site into which SRahOTC was inserted ( 16) . pHCMVsplA, the plasmid into which the lacZ gene was inserted, was generated from pXC I by deleting Ad5 sequences from the SspI site at 339 bp to the A fIII site at 3,533 bp. This deletion removes the spII binding site (3,525-3,530 bp) from the protein IX promoter that was reintroduced 1 bp closer to the protein IX TATA box. Various unique cloning sites and the human cytomegalovirus (HCMV) promoter were introduced into the deletion. One other difference between pHCMVsplA and pXCI is that -400 bp of pBR322 sequences were removed between the EcoRI and BamHI sites. The lacZ gene with the SV40 poly A signal was inserted between the SalI and XbaI sites of pHCMVsplA generating pHCMVsplLacZ. Both pAdSRahOTC and pHCMVspl LacZ were rescued into virus by cotransfection with pJM17 (17) .
Hepatocyte cultures. Human liver segments preserved in University of Wisconsin solution ( 18) for liver transplantation were obtained after reduction through the liver tissue procurement and distribution system (19) . Under aseptic conditions, -40 g of the liver were removed, and hepatocytes were isolated according to Ledley et al. (20) . Hepatocytes were infected with recombinant adenoviruses, AdHCMVsplLacZ and AdSRahOTC, as described by Graham and Prevec (9) . Cells were exposed to the viral suspensions 48 h after plating for I h at room temperature with a range of multiplicities of infection, based on plaque-forming units (pfu) defined on the 293 cell line (21 ) . Controls were subjected to the same infection conditions, except that virus-free suspension buffer was used (phosphate-buffered saline with Ca2", Mg2", and 10% glycerol). I h after infection, cells were washed with phosphate buffered saline followed by the addition ofculture media. Mouse-derived hepatocytes cultures were prepared essentially as described by Grompe et al. (1) . Histochemical staining. Cells were fixed and evaluated for the expression of Escherichia coli 3gal enzyme activity after staining with 5-bromo-4-chloro-3-indolyl-13, D-galactosidase (X-gal stain), and a, antitrypsin. Cultures were fixed in 0.5% glutaraldehyde (Sigma Immunochemicals, St. Louis, MO) and stained as described (22) . For immunohistochemical staining, cultures were fixed in 0.5% glutaraldehyde and incubated with a 1:1,200 dilution of rabbit anti-a, antitrypsin antibody (Atlantic Antibodies, Scarborough, ME). Immunoperoxidase staining was performed using the Vectastain ABC method (Vector Laboratories, Inc., Burlingame, CA), and hematoxylin was used as a counter stain.
OTC assay. Cells were harvested by scraping into 0.25 M Tris/ HCI, In vivo viral delivery. 2-mo-old C3H/HENCRMTV mice were anesthetized and their abdomens were opened, exposing the portal vein or the spleen. Intraportal or intrasplenic injections with I X 10 0' and 2 X 10 10 pfu ofAdHCMVspl LacZ in 100 and 200 ,l ofviral suspension buffer (PBS ++ plus 10% glycerol), respectively, or with virus-free suspension buffer were performed using a 30-gauge needle.
Frozen sections. Liver tissue was snap frozen by plunging into liquid nitrogen-cooled isopentane. 8-Mm sections were fixed in 2.5% glutaraldehyde and stained with X-gal as described (22) .
Results
Adenoviral-mediated gene expression in human hepatocytes. Cultured human hepatocytes infected with recombinant adenovirus efficiently expressed exogenous genes. We constructed and used an Ad vector (AdHCMVsplLacZ) carrying an early region 1 (El ) substitution of an expression cassette consisting of HCMV immediate early gene promoter driving bacterial flgal expression to infect human hepatocytes. Cultures were infected with AdHCMVsplLacZ at different moi ( Fig. 1 , C-G). 100% of the cells expressed figal when infected at an moi of 200 or 400 pfu/cell at 72 h and < 2 wk after infection (Fig. 2 ).
Cells infected at moi's of 10, 20, 50, and 100 yielded expression ranging from 2 to 84% (Fig. 2) .
With respect to cell morphology ( Fig. 1, B , C-G) and endogenous OTC activity (Fig. 3) , infected cultures were comparable to controls. The culture conditions used select against nonhepatocyte liver cells (23) , and > 95% of the surviving cells were hepatocytes, as shown by morphology and immunohistochemical staining with antibody to the hepatocyte-specific enzyme marker, aI antitrypsin ( Fig. 1 A) .
Adenoviral-mediated expression in vivo. Adult mice were used to evaluate the efficiency of adenoviral gene transduction in vivo. Estimation of the proportion of cells expressing fl-galactosidase (,8-gal) from frozen sections was difficult because of the patchy distribution of expressing cells (Fig. 4 B) . Some areas were densely stained, while others showed sparse staining with no apparent overall pattern. Therefore, for a more reliable estimate of transduction, livers were cultured, and 24 h after plating, they were fixed, stained, and evaluated ( Fig. 4 A) . Splenic (n = 8) or intraportal (n = 8) infusions of 1 x 1010 and 2 X 1010 pfu resulted in 21.6±7.5 and 42.4±6.7% of cells expressing #gal activity 72 h after infection, respectively. Livers perfused and stained in situ 72 h after infection showed an overall positive (3gal staining with no confinements to any specific area or lobe of the liver (Fig. 5 ). No morphologic differences (gross or microscopic) were found between control (uninfected, AdSRahOTC, or viral suspension buffer-mock infected) and AdHCMVsplLacZ-infected mice, and no background staining was found in control livers ( Fig. 1 B and  Fig. 5 ).
OTC correction in vitro. Hepatocytes derived from sparse fur (spf) mice with > 80% reduction in endogenous OTC activity were infected 48 h after plating with AdSRahOTC. 1 wk after infection, OTC activity was assayed. The percentage of OTC activity detected in hepatocytes infected with AdSRahOTC ranging from 1 to 200 moi ranged between 26 and 151% relative to wild type-derived hepatocytes uninfected or infected with AdHCMVspl LacZ (Fig. 6 ). AdSRahOTC was also used to infect OTC-deficient primary human hepatocytes isolated from a severely affected patient undergoing liver transplant. Preliminary data show an increase in OTC activity 4 d after infection (Fig. 7 ).
Discussion
Our results show that essentially all of the primary human hepatocytes in culture that were infected with AdHCMVsp I LacZ at moi's of 200 or 400 expressed (3gal activity. Ad mutants defective in postinfection functions, and to a much lesser extent, mutants deleted in El, can show multiplicity-dependent leakiness in certain cells, particularly at very high pfu/cell ratio (24, 25) . Exposure of human hepatocytes to the high moi's used in these studies did not alter endogenous OTC enzyme activity levels. Furthermore, no cytopathic effects were observed for as long as 2 wk after infection, and no morphological differences were observed between recombinant virus-infected and uninfected cultures, suggesting that significant levels of virus replication were not occurring.
In vivo, single injections of AdHCMVsplLacZ (2 X 1010 pfu/ml) targeted to the liver in adult mice resulted in > 40% of~d V~~ko %/~W / J *w q WWW\ Ao\S (5) . This difference may relate to several factors, including the difference in vectors used, promoters, and the amount of recombinant virus injected in relation to the size ofthe animal (25-30 g/mouse vs 250-300 g/rat). We anticipate that with our vectors, even higher levels ofactivity may be obtained with minor technical modifications, such as increasing the moi, the time, or repeated inoculation. (26) , and the levels ofactivity equaled or exceeded those ofwild type controls. We report the first successful attempt for OTC gene augmentation in human hepatocytes derived from an OTC-deficient patient resulting in an increase in enzyme activity. The wild type levels of OTC expression achieved in this report are the~first demonstration of complete correction for the deficiency in vitro. This is significant in terms ofOTC gene therapy and in vivo targeting of the liver. We therefore predict, based (27, 28) . Furthermore, while this paper has focused on hepatic expression; ectopic expression of OTC in the small bowels of transgenic sparse fur mice corrected the urea cycle metabolic defect (2) . These features offer many logical approaches to gene therapy "correction" of OTC deficiency. Strong expression of OTC in deficient patients during a hyperammonemic crisis could be ofgreat benefit, even if the expression is transient. Currently available adenoviral vectors may not support permanent gene expression, because they are not incorporated into the host cell genome. Therefore, the strength of a promoter in such a system may be more relevant than the longevity ofthe expression. However, for permanent gene therapy, liver-specific or long-term promoters should be of potential benefit. The safety of adenovirus vectors is an issue that requires further study. Although the adenovirus serotypes 4 and 7 have been used for decades as oral vaccines without significant complications, there are still potential hazards (27) (28) (29) (30) . This issue is particularly critical in terms of assessing the safety of the currently used replication-defective adenoviruses, since replication-defective adenoviruses lacking after infection can be partially complemented not only by wild type adenovirus, but also by heterologous immediate early proteins of other viruses including HCMV and EBV (31) (32) (33) . Although the liver is a rare target for clinical adenoviral infection, it can be a target for HCMV ( 34, 35 ) . Viral vectors deleted in all El functions both after infection and El B, are less likely to manifest leakiness at high mois or be complemented by early functions of heterologous viruses. Nevertheless additional studies are required to evaluate the usefulness of the currently available defective adenovirus vectors and to determine whether additional alterations may be desirable. It is noteworthy in this context that a vast array of Ad mutants, temperature-sensitive in viral functions, is available to generate vectors which are impaired if necessary.
This study suggests that adenoviral vectors may provide a powerful tool for transduction of high level gene expression in the liver and moves us one more step toward clinical gene therapy trials. In the case of OTC deficiency, shortand/or long-term expression would have utility.
